Nov 12, 2020 / 08:00AM GMT
Carlos de Sousa - Ultimovacs ASA - CEO
Good morning, everybody. My name is Carlos de Sousa, and I want to welcome you to our third-quarter presentation. I'm here with my colleagues Jens Bjørheim, our Chief Medical Officer; and Hans Eid, our Chief Financial Officer. So, let me give you the highlights of this third quarter. Jens will then cover updates on our clinical program, Hans will cover the financials, and then all of us will be available to answer your questions. So please, if you have any questions, send it to us and we will try to answer as many as possible.
So, this was a very good quarter for Ultimovacs. The Phase 2 INITIUM trial has now 12 patients enrolled versus the three patients that we had at the end of the second quarter. And the Phase 2 NIPU trial is now six patients enrolled versus the four patients at the end of the second quarter.
The COVID-19 pandemic has had, so far, limited impact regarding site opens and the patient enrolment. But of course, as for all other industry biotechs, big pharma, and society in general, we don't know in the future what is the potential
Q3 2020 Ultimovacs ASA Earnings Call Transcript
Mar 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers